Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia

Blood. Volume 115, Issue 7: p.1394-1405, 30 October 2009, 10.1182/blood-2009-05-218560

To determine whether gene expression profiling could improve outcome prediction in children with acute lymphoblastic leukemia (ALL) at high risk for relapse, we profiled pretreatment leukemic cells in 207 uniformly treated children with high-risk B-precursor ALL. A 38-gene expression classifier predictive of relapse-free survival (RFS) could distinguish 2 groups with differing relapse risks: low (4-year RFS, 81%, n = 109) versus high (4-year RFS, 50%, n = 98; P < .001). In multivariate analysis, the gene expression classifier (P = .001) and flow cytometric measures of minimal residual disease (MRD; P = .001) each provided independent prognostic information. Together, they could be used to classify children with high-risk ALL into low- (87% RFS), intermediate- (62% RFS), or high- (29% RFS) risk groups (P < .001). A 21-gene expression classifier predictive of end-induction MRD effectively substituted for flow MRD, yielding a combined classifier that could distinguish these 3 risk groups at diagnosis (P < .001). These classifiers were further validated on an independent high-risk ALL cohort (P = .006) and retainedindependent prognostic significance (P < .001) in the presence of other recently described poor prognostic factors (IKAROS/IKZF1 deletions, JAK mutations, and kinase expression signatures). Thus, gene expression classifiers improve ALL risk classification and allow prospective identification of children who respond or fail current treatment regimens. These trials were registered at http://clinicaltrials.gov under NCT00005603 (http://clinicaltrials.gov/show/NCT00005603).

Supplemental Data Files

• GDC Manifests
  • Controlled-Access Data Download Manifest (5 Files)
  • Open-Access Data Download Manifest (17 Files)

• Copy Number Array
  • TARGET ALL P1 Copy Number Array Level 1 Data (Controlled)
  • TARGET ALL P1 Copy Number Array Level 2 Data (Controlled)
  • TARGET ALL P1 Copy Number Array Level 3 Data
  • TARGET ALL P1 Copy Number Array Level 4 Data
  • TARGET ALL P1 Copy Number Array Metadata
• Gene Expression
  • TARGET ALL P1 Gene Expression Array Level 1 Data
  • TARGET ALL P1 Gene Expression Array Level 2 Data
  • TARGET ALL P1 Gene Expression Array Level 3 Data
  • TARGET ALL P1 Gene Expression Array Level 4 Data
  • TARGET ALL P1 Gene Expression Array Metadata
• mRNA-Seq
  • TARGET ALL P1 mRNA-seq Level 3 Data
  • TARGET ALL P1 mRNA-seq Level 3 Data (Controlled)
  • TARGET ALL P1 mRNA-seq Metadata
• Kinome
  • TARGET ALL P1 Kinome Metadata
  • TARGET ALL P1 Kinome Level 1 Data (Controlled)
• WGS
  • TARGET ALL P1 and P2 WGS L3 Data
  • TARGET ALL P1 and P2 WGS L3 Data (Controlled)
  • TARGET ALL P1 and P2 WGS L4 Data
  • TARGET ALL P1 and P2 WGS Metadata
• Additional Information
  • TARGET ALL P1 Sample Matrix
  • TARGET ALL P1 ID Mapping Information

Additional Resources

• TARGET ALL P1 at SRA (link is external) NCBI

Instructions for Data Download

Open Access Data

1. Download the appropriate manifest file from the publication page
2. Use the manifest file to download data using the GDC Data Transfer Tool (DTT) or the GDC API
   • GDC DTT (Download, User's Guide)
   • GDC API (User’s Guide)

Controlled Access Data

1. Download the appropriate manifest file from the publication page
2. Download a token from the GDC Data Portal
   • GDC Data Portal (Launch, User’s Guide)
3. Use the manifest file and token to download data using the GDC DTT or the GDC API
   • GDC DTT (Download, User’s Guide)
   • GDC API (User’s Guide)

For assistance, please contact the GDC Help Desk: support@nci-gdc.datacommons.io